Scott D Solomon, John W Ostrominski, Muthiah Vaduganathan, Brian Claggett, Pardeep S Jhund, Akshay S Desai, Carolyn S P Lam, Bertram Pitt, Michele Senni, Sanjiv J Shah, Adriaan A Voors, Faiez Zannad, Imran Zainal Abidin, Marco Antonio Alcocer-Gamba, John J Atherton, Johann Bauersachs, Chang-Sheng Ma, Chern-En Chiang, Ovidiu Chioncel, Vijay Chopra, Josep Comin-Colet, Gerasimos Filippatos, Cândida Fonseca, Grzegorz Gajos, Sorel Goland, Eva Goncalvesová, Seok-Min Kang, Tzvetana Katova, Mikhail N Kosiborod, Gustavs Latkovskis, Alex Pui-Wai Lee, Gerard C M Linssen, Guillermo Llamas-Esperón, Vyacheslav Mareev, Felipe A Martinez, Vojtěch Melenovský, Béla Merkely, Savina Nodari, Mark C Petrie, Clara Inés Saldarriaga, Jose Francisco Kerr Saraiva, Naoki Sato, Morten Schou, Kavita Sharma, Richard Troughton, Jacob A Udell, Heikki Ukkonen, Orly Vardeny, Subodh Verma, Dirk von Lewinski, Leonid G Voronkov, Mehmet Birhan Yilmaz, Shelley Zieroth, James Lay-Flurrie, Ilse van Gameren, Flaviana Amarante, Prabhakar Viswanathan, John J V McMurray
AIMS: To describe the baseline characteristics of participants in the FINEARTS-HF trial, contextualized with prior trials including patients with heart failure (HF) with mildly reduced and preserved ejection fraction (HFmrEF/HFpEF). The FINEARTS-HF trial is comparing the effects of the non-steroidal mineralocorticoid receptor antagonist finerenone with placebo in reducing cardiovascular death and total worsening HF events in patients with HFmrEF/HFpEF. METHODS AND RESULTS: Patients with symptomatic HF, left ventricular ejection fraction (LVEF) ≥40%, estimated glomerular filtration rate ≥ 25 ml/min/1...
May 11, 2024: European Journal of Heart Failure